The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma

BackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive disease without standardized treatment strategies. The efficacy of second-line or beyond immune checkpoint inhibitors (ICIs) has been proven in recent studies, whereas the evidence for first-line immunotherapy for PSC is still...

Full description

Bibliographic Details
Main Authors: Zhimin Zeng, Xiaoying Qian, Fanrong Liu, Yong Wang, Yong Yuan, Chen Fang, Xinwei Zhang, Shangkun Yuan, Renfang Chen, Biao Yu, Tong Wang, Yan Yin, Yong Li, Anwen Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
pulmonary sarcomatoid carcinoma
immune checkpoint inhibitors
immunotherapy
anlotinib
camrelizumab
tislelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.956982/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.956982/full

Similar Items